Argenx announces publication in the lancet neurology of pivotal adhere study data in chronic inflammatory demyelinating polyneuropathy

Adhere was largest and most innovative clinical trial of cidp patients to date vyvgart® hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action vyvgart hytrulo is first and only neonatal fc receptor (fcrn) blocker fda-approved to treat cidp september 19, 2024 – 7:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced publication in the lancet neurology of the pivotal adhere study, the largest clinical trial to date in chronic inflammatory demyelinating polyneuropathy (cidp). cidp is a rare, debilitating, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system.
ARGX Ratings Summary
ARGX Quant Ranking